Swiss biotech Bioversys' shares open slightly higher on stock market debut
07/02/2025 08:22
Feb 7 (Reuters) - Swiss biotech Bioversys AG BIOV.S
shares started trading at 36.5 Swiss francs ($40.29) on the SIX
Swiss Exchange on Friday, slightly up from the final price for
its initial public offering (IPO) of 36 Swiss francs per share.
BioVersys, which researches and develops novel antibacterial
products for serious life-threatening infections caused by
multidrug-resistant (MDR) bacteria, will use most of its
proceeds from the IPO towards the development of its BV100
treatment for infections linked to ventilator-associated
pneumonia and bloodstream infections.
($1 = 0.9060 Swiss francs)
(Reporting by Linda Pasquini)
((linda.pasquini@thomsonreuters.com; +48 58 7785261;))
Recent news on BioVersys AG
See all newsBrief: Bioversys Expects Total Operating Loss Of CHF 40-45 Mln For FY2026
RCS - Bio Versys AG - BioVersys and partners’
Brief: BioVersys Announces BV100 Phase 3 Initiation And Provides Business Update
Brief: Bioversys Says Patent Claims For Its BV100 Drug Candidate Have Been Granted In China
UBS, Stifel start coverage of BioVersys with 'buy;' shares climb